List of Excipients in Branded Drug HYPERRAB

« Back to Dashboard

# HYPERRAB Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: September 24, 2026

HyperRAB is a plasma-derived rabies immune globulin used for post-exposure prophylaxis with rabies vaccine. Its commercial differentiation is driven mainly by antibody potency, plasma supply, manufacturing controls, concentration, administration volume, and distribution rather than by a complex excipient system. FDA labeling identifies glycine as the principal inactive ingredient and states that the product contains no preservative.[1]

The strongest excipient opportunities are concentrated in formulation stability, container-closure compatibility, low-volume delivery, cold-chain resilience, and supply assurance for compendial glycine. Excipient changes would require a biologics comparability strategy because changes can affect IgG aggregation, potency, safety, viscosity, and local tolerability.

What excipients are used in HyperRAB?

HyperRAB 300 IU/mL contains human rabies immune globulin as its active biological component and glycine as the labeled stabilizing excipient. The product is supplied as a sterile, preservative-free solution for injection.[1]

Attribute	HyperRAB position
Active ingredient	Rabies immune globulin, human
Antibody class	Predominantly IgG
Strength	300 IU/mL for the current concentrated presentation
Primary excipient identified in labeling	Glycine
Preservative	None
Dosage form	Sterile injectable solution
Administration	Infiltration around the wound, with any remainder administered intramuscularly
Product category	Plasma-derived biologic
Primary commercial use	Rabies post-exposure prophylaxis

Glycine is used as a stabilizer and tonicity-supporting component. Its value in HyperRAB is functional rather than proprietary. The commercial opportunity is therefore more likely to arise from tighter control of excipient quality and formulation performance than from ownership of glycine itself.

The product’s formulation must preserve rabies-neutralizing antibody activity during manufacturing, storage, transport, and administration. Relevant quality attributes include:

• IgG monomer content;
• aggregate and fragment levels;
• rabies virus neutralizing antibody potency;
• visible and subvisible particles;
• pH and osmolality;
• protein concentration;
• sterility and endotoxin;
• extractables and leachables;
• container-closure integrity.

How does HyperRAB’s excipient strategy compare with competing rabies immune globulins?

HyperRAB competes primarily with KEDRAB, another FDA-approved human rabies immune globulin. The commercial comparison is based less on differentiated excipients than on concentration, presentation, hospital contracting, availability, price, and manufacturer supply reliability.

Product	Manufacturer	Concentration commonly marketed	Excipient strategy	Commercial implication
HyperRAB	Grifols	300 IU/mL	Glycine-containing, preservative-free solution	Lower injection volume than 150 IU/mL products
KEDRAB	Kedrion Biopharma	150 IU/mL	Product-specific stabilizer system	Larger administration volume at equivalent IU dose
Older rabies immune globulin presentations	Various plasma-product manufacturers	Often 150 IU/mL	Product-specific formulations	Competition depends on availability and contracts

At 300 IU/mL, HyperRAB can reduce the volume required to deliver a fixed international-unit dose. That matters because rabies immune globulin must be infiltrated into and around the wound when anatomically feasible. A concentrated product can reduce the burden of dividing a dose across multiple wounds or managing limited tissue space.

The concentration advantage does not eliminate formulation constraints. Higher protein concentration can increase viscosity, aggregation risk, injection force, and sensitivity to agitation or temperature excursions. Any excipient or container change must be assessed against those risks.

What formulation opportunities exist for HyperRAB?

The most credible opportunities are incremental formulation and presentation improvements rather than a new excipient platform.

Higher-concentration presentations

A future 450 IU/mL or 600 IU/mL presentation could reduce administration volume further. The commercial case would depend on:

• acceptable viscosity;
• reliable syringeability through practical needle gauges;
• preservation of antibody potency;
• low aggregate formation;
• sufficient wound-infiltration flexibility;
• approval of the new strength and presentation.

Higher concentration can create a meaningful product distinction in emergency departments and hospitals, but the formulation burden rises sharply as protein concentration increases.

Improved low-temperature stability

A formulation with greater tolerance to short-term temperature excursions could reduce product loss across emergency-department inventories, ambulances, rural hospitals, and international distribution channels. Potential approaches include screening alternative amino-acid stabilizers, polyols, sugars, or surfactants.

Any substitution for glycine would require a structured comparability package. The sponsor would need to demonstrate that the new formulation does not change potency, aggregate levels, immunogenicity risk, degradation pathways, or administration tolerability.

Reduced aggregation and particle formation

A controlled surfactant strategy could reduce interface-induced aggregation during filling, shipping, and injection. Surfactants such as polysorbates are common in protein products, but they can introduce oxidation, hydrolysis, peroxide, and subvisible-particle issues. The approved HyperRAB labeling should be treated as the controlling source for the commercial formulation; an excipient identified in a manufacturing process is not necessarily present in the final drug product.[1]

Commercially valuable development work would include:

• low-peroxide surfactant grades;
• oxidation-resistant excipient supply;
• agitation studies;
• silicone-oil interaction studies;
• compatibility with prefilled syringes;
• particle-control methods.

Prefilled syringe or ready-to-use delivery

A prefilled syringe could reduce preparation time and medication-error risk. The design would require compatibility testing with elastomers, lubricants, tungsten residues, silicone oil, syringe barrels, and needle systems.

The commercial benefit is strongest for emergency settings where rapid administration matters. The principal barriers are product stability, syringeability, dose accuracy, container-closure validation, and the need to demonstrate that the device does not alter antibody quality.

What patents protect HyperRAB and its formulation?

Publicly available FDA labeling identifies the approved product and formulation characteristics but does not establish a broad, commercially blocking excipient patent estate.[1] HyperRAB is a biologic, so its core regulatory protection is not evaluated through the conventional small-molecule Orange Book framework.

Potentially relevant intellectual-property categories include:

1. composition-of-matter claims covering rabies immune globulin preparations;
2. plasma fractionation and purification processes;
3. solvent-detergent or viral-inactivation processes;
4. concentration and stabilization methods;
5. container-closure systems;
6. dosing and wound-infiltration methods;
7. high-concentration or reduced-volume presentations;
8. manufacturing controls that preserve neutralizing-antibody potency.

A claim directed broadly to glycine in an immunoglobulin formulation would face substantial validity and enforceability challenges because glycine is a well-known protein stabilizer. Stronger protection would more likely require a specific concentration range, pH window, stability result, antibody profile, manufacturing condition, or device combination.

No reliable commercial conclusion should be drawn from an unverified patent number. Patent-family analysis must distinguish granted claims from abandoned applications, expired claims, terminal disclaimers, continuations, and patents that do not cover the marketed formulation.

What is the Orange Book and FDA regulatory status of HyperRAB?

HyperRAB is regulated as a biologic under a biologics license application rather than as a conventional small-molecule drug. The Orange Book is therefore not the principal source for its exclusivity or patent status.[2]

Relevant regulatory sources include:

• FDA-approved prescribing information;
• FDA’s biologics licensing records;
• the Purple Book for reference biological products and related exclusivity information;
• FDA guidance on comparability and manufacturing changes;
• USPTO records for formulation, manufacturing, and device patents.

Rabies immune globulin is not a biosimilar-driven category in the same manner as insulin, monoclonal antibodies, or other high-volume biologics. A biosimilar or interchangeable product would need to satisfy the statutory and regulatory requirements for biosimilarity, including analytical and clinical justification appropriate to the product.[3]

When does HyperRAB lose exclusivity?

HyperRAB does not have a simple small-molecule patent-expiration date that determines generic entry. Market entry depends on the status of the biologics license, regulatory exclusivity, any valid patents, manufacturing capability, and access to qualified human plasma.

The commercial timeline is better understood as follows:

Protection or barrier	Relevance to HyperRAB
Small-molecule NCE exclusivity	Not the governing framework
Orange Book listing	Generally not the primary patent source for this biologic
Biologic regulatory exclusivity	Potentially relevant depending on the approved reference-product status and applicable statutory pathway
Formulation patents	May restrict specific concentration or stabilizer combinations
Process patents	May restrict manufacturing routes but often do not block all alternative processes
Plasma supply	Major practical entry barrier
FDA approval	Required for a competing biological product
Hospital contracts	Can delay or limit commercial uptake even after approval

A competitor can avoid a process patent by using a non-infringing purification, viral-inactivation, or formulation process. That makes manufacturing know-how important but does not automatically create a durable product monopoly.

What Paragraph IV challenges and litigation affect HyperRAB?

Paragraph IV litigation is principally associated with abbreviated new drug applications and Orange Book-listed patents. It is not the expected primary challenge mechanism for a plasma-derived biologic such as HyperRAB.

Potential disputes would more likely involve:

• BLA-related patent litigation;
• manufacturing-process claims;
• formulation claims;
• trade-secret disputes;
• biosimilar patent-exchange procedures;
• regulatory exclusivity;
• procurement and supply contracts.

No verified, product-specific litigation outcome should be assigned without current court-docket and patent-record review. The absence of a conventional Paragraph IV pathway does not mean the product is free of litigation risk; it means the risk is structured differently.

Which companies could challenge HyperRAB commercially?

The credible competitive set includes manufacturers with:

• licensed rabies immune globulin products;
• access to qualified plasma donors;
• validated viral-clearance processes;
• global fractionation capacity;
• hospital and public-health distribution;
• the ability to maintain emergency inventory.

Kedrion is the most direct branded competitor through KEDRAB. Other competition can arise from regional or imported rabies immune globulin products, subject to FDA approval and supply requirements.

The largest barrier is not the cost of glycine. It is the integrated manufacturing system required to collect or source plasma, produce consistent high-titer IgG, remove or inactivate pathogens, fill sterile injectable product, and maintain reliable supply.

What commercial opportunities exist for excipient suppliers?

The best opportunities are quality- and performance-driven.

Compendial glycine supply

Suppliers can compete on:

• low bioburden and endotoxin;
• trace-metal control;
• lot-to-lot consistency;
• documentation and auditability;
• dual-site manufacturing;
• pharmaceutical-grade regulatory support;
• supply continuity.

A supplier that qualifies as an alternate source can gain value because changing excipient suppliers in a biologic may require comparability work and regulatory reporting.

Protein-stabilization platforms

Excipient developers can evaluate:

• amino-acid combinations;
• polyol or sugar stabilizers;
• surfactant systems;
• low-peroxide excipients;
• lyophilization-compatible systems;
• formulations designed for high protein concentration.

The commercial target is not merely improved shelf life. It is a measurable reduction in aggregation, particles, potency loss, shipping failures, or cold-chain expense.

Primary packaging

Glass vials remain practical for low-volume biologics, but prefilled syringes and polymer-based systems could create differentiation. Suppliers of coated elastomers, low-extractable components, and low-silicone delivery systems may have a stronger commercial position than suppliers offering another generic buffer component.

Manufacturing and analytical services

Contract development organizations can offer:

• forced-degradation studies;
• formulation screening;
• high-concentration protein analytics;
• particle characterization;
• container-closure compatibility;
• comparability protocols;
• process validation;
• stability programs.

These services can support both lifecycle management and competitive product development.

How strong is HyperRAB’s patent estate?

HyperRAB’s practical protection appears stronger in manufacturing complexity, plasma access, regulatory history, and distribution than in a simple excipient patent. Glycine alone is unlikely to create a durable blocking position.

Protection area	Relative strength
Glycine composition claim	Low to moderate
High-concentration formulation	Moderate if claims are narrow and technically supported
Manufacturing process	Moderate to strong when difficult to design around
Plasma sourcing	Strong practical barrier, but not necessarily an enforceable patent barrier
Delivery device	Moderate, depending on claim scope
Regulatory approval and quality history	Strong commercial barrier
Hospital distribution	Strong commercial advantage but contract-dependent

The most defensible lifecycle strategy would combine a concentrated presentation, validated container system, stable supply chain, and narrowly drafted formulation or device claims supported by comparative stability data.

What generic or biosimilar entry risks exist?

Near-term entry risk is more likely to arise from another plasma-derived rabies immune globulin than from a conventional generic. A successful entrant would need to match or exceed:

• rabies virus neutralizing potency;
• safety and viral-clearance profile;
• administration usability;
• product availability;
• price;
• emergency procurement performance.

A lower-priced 150 IU/mL product could compete effectively despite requiring more volume. A concentrated 300 IU/mL or higher product would have a stronger clinical-workflow proposition but face greater technical and regulatory complexity.

Key Takeaways

• HyperRAB is a preservative-free, plasma-derived rabies immune globulin product whose labeled excipient strategy centers on glycine.[1]
• Its commercial differentiation comes mainly from 300 IU/mL concentration, reduced administration volume, antibody potency, supply reliability, and hospital distribution.
• The most valuable excipient opportunities involve stability, aggregation control, low-peroxide materials, temperature-excursion tolerance, and container compatibility.
• Orange Book and Paragraph IV frameworks are not the primary tools for evaluating HyperRAB exclusivity.
• Plasma sourcing, fractionation, viral clearance, quality systems, and FDA approval are larger entry barriers than glycine access.
• A future prefilled syringe or higher-concentration presentation could create lifecycle value if viscosity, stability, and injection performance remain acceptable.
• HyperRAB’s strongest protection is likely operational and regulatory rather than a broad excipient patent.

FAQs

Is glycine in HyperRAB a patentable commercial advantage?

Glycine itself is unlikely to provide meaningful exclusivity. A narrow formulation claim could have value if it links glycine concentration, pH, protein concentration, and stability performance to a technically demonstrated result.

Can HyperRAB be reformulated with sucrose or trehalose?

Potentially, but the change would require formulation development, analytical comparability, stability testing, and appropriate FDA reporting or approval. The sponsor would need to show that potency, aggregation, safety, and administration characteristics remain controlled.

Does HyperRAB have an Orange Book patent expiration date?

The Orange Book is not the primary exclusivity source for this biologic. Patent, regulatory, and market-entry analysis should focus on BLA status, Purple Book information where applicable, USPTO records, and manufacturing barriers.

Would a 600 IU/mL rabies immune globulin be commercially attractive?

It could reduce injection volume, but the value would depend on viscosity, wound-infiltration practicality, aggregate control, syringeability, and FDA approval. Higher concentration alone would not guarantee adoption.

What is the biggest barrier to a competing HyperRAB product?

The largest barrier is an integrated plasma-derived manufacturing platform with qualified raw material, validated pathogen reduction, consistent high-titer antibody production, sterile filling, regulatory support, and reliable emergency distribution.

References

1. U.S. Food and Drug Administration. (n.d.). HyperRAB: Rabies immune globulin (human) prescribing information. Grifols Therapeutics LLC.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

3. U.S. Food and Drug Administration. (2015). Scientific considerations in demonstrating biosimilarity to a reference product. FDA.